Open original FDA record ↗Recall record
- FDA identifier
- Z-0290-2018
- Company in FDA record
- Remel Inc
- FDA record creation date
- Dec 26, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The serum may fail to agglutinate within the specified minimum reaction time.
Source facts
- Action
- The recalling firm issued letters dated 12/8/2017 via regular mail. The letter identified the affected product, problem and actions to be taken. The risk to health is also explained. The customer is requested to notify any personnel who need to be aware of the potential for incorrect performance specification for the product. The customer is to inspect their stock and destroy any remaining inventory of the lots listed. They are to contact Customer Service or their local distributor for replacement. A response form was to be returned acknowledging receipt of the notice and disposal of the affected product. If the product was further distributed, the customer was requested to contact their downstream customers, advise them of the recall, and provide them a copy of the recall letter.
- Initiated
- 2017-12-08
- Root cause
- Under Investigation by firm
- Terminated
- 2020-07-22
- Distribution
- US Nationwide Distribution
- Recall number
- Z-0290-2018
- Recall status
- Terminated
- CDRH record ID
- 160235
- FDA record created
- 2017-12-26
- Recall event number
- 78728